|
Gene: TCFL5 |
Gene summary for TCFL5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TCFL5 | Gene ID | 10732 |
Gene name | transcription factor like 5 | |
Gene Alias | CHA | |
Cytomap | 20q13.33 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q86TP4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10732 | TCFL5 | HCC1_Meng | Human | Liver | HCC | 6.88e-15 | 1.81e-02 | 0.0246 |
10732 | TCFL5 | HCC2_Meng | Human | Liver | HCC | 5.98e-03 | 2.94e-02 | 0.0107 |
10732 | TCFL5 | HCC1 | Human | Liver | HCC | 2.43e-02 | 1.67e+00 | 0.5336 |
10732 | TCFL5 | HCC2 | Human | Liver | HCC | 1.02e-04 | 1.42e+00 | 0.5341 |
10732 | TCFL5 | S028 | Human | Liver | HCC | 8.47e-08 | 2.60e-01 | 0.2503 |
10732 | TCFL5 | male-WTA | Human | Thyroid | PTC | 1.49e-04 | 6.49e-02 | 0.1037 |
10732 | TCFL5 | PTC06 | Human | Thyroid | PTC | 2.76e-06 | 9.94e-02 | 0.2057 |
10732 | TCFL5 | ATC12 | Human | Thyroid | ATC | 9.43e-07 | 1.31e-01 | 0.34 |
10732 | TCFL5 | ATC13 | Human | Thyroid | ATC | 8.98e-25 | 5.00e-01 | 0.34 |
10732 | TCFL5 | ATC4 | Human | Thyroid | ATC | 1.36e-11 | 1.64e-01 | 0.34 |
10732 | TCFL5 | ATC5 | Human | Thyroid | ATC | 5.27e-33 | 5.59e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TCFL5 | SNV | Missense_Mutation | c.1096N>A | p.Gly366Ser | p.G366S | Q9UL49 | protein_coding | tolerated(0.59) | possibly_damaging(0.738) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TCFL5 | SNV | Missense_Mutation | rs763542036 | c.1415G>A | p.Arg472Gln | p.R472Q | Q9UL49 | protein_coding | tolerated(0.07) | benign(0.097) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
TCFL5 | insertion | Frame_Shift_Ins | novel | c.774_775insGTGGGAG | p.Leu259ValfsTer12 | p.L259Vfs*12 | Q9UL49 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
TCFL5 | deletion | Frame_Shift_Del | novel | c.1257_1269delNNNNNNNNNNNNN | p.Cys419Ter | p.C419* | Q9UL49 | protein_coding | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
TCFL5 | deletion | Frame_Shift_Del | novel | c.1053delN | p.Asp351GlufsTer4 | p.D351Efs*4 | Q9UL49 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
TCFL5 | SNV | Missense_Mutation | novel | c.1282C>T | p.Pro428Ser | p.P428S | Q9UL49 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TCFL5 | SNV | Missense_Mutation | rs763542036 | c.1415N>A | p.Arg472Gln | p.R472Q | Q9UL49 | protein_coding | tolerated(0.07) | benign(0.097) | TCGA-XS-A8TJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
TCFL5 | SNV | Missense_Mutation | rs778322425 | c.740N>T | p.Ala247Val | p.A247V | Q9UL49 | protein_coding | tolerated(0.1) | possibly_damaging(0.557) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TCFL5 | SNV | Missense_Mutation | rs767486884 | c.1042N>T | p.Arg348Cys | p.R348C | Q9UL49 | protein_coding | tolerated(0.06) | possibly_damaging(0.759) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TCFL5 | SNV | Missense_Mutation | c.1426N>A | p.Leu476Met | p.L476M | Q9UL49 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.916) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |